{"id":5283,"date":"2014-11-27T10:12:51","date_gmt":"2014-11-27T10:12:51","guid":{"rendered":"\/?p=5283"},"modified":"2014-11-27T10:27:17","modified_gmt":"2014-11-27T10:27:17","slug":"cellceutix-corp-otcmktsctix-surging-on-pr","status":"publish","type":"post","link":"\/articles\/cellceutix-corp-otcmktsctix-surging-on-pr\/","title":{"rendered":"Cellceutix Corp (OTCMKTS:CTIX) Surging On PR"},"content":{"rendered":"\n

Cellceutix Corp (OTCMKTS:CTIX<\/a>) has experienced four consecutive positive sessions and has increased its market price by approximately 11%. After yesterday’s gain of 0.63% on a volume of 386 thousand shares, the stock closed at $3.20.<\/p>\n

The most recent news on the company comes from a press release CTIX<\/a> <\/strong>issued yesterday several hours before the opening bell. The PR disclosed that December will be a “momentous month<\/em>” for the company. <\/p>\n

The release starts by announcing that the ninth cohort’s Phase 1 Kevetrin clinical trials “for advanced solid tumors<\/em>” have ended. Then states that in the “first week of December<\/em>” the collected safety data will be reviewed, but the announcements for the following month don’t stop there.<\/p>\n

In December the tenth cohort will undergo Kevetrin trials. The company and the University of Bologna will meet in order to discuss “the Phase 1\/2 trial of Kevetrin in combination with cytarabine in patients with Acute Myelogenous Leukemia”<\/em>. The Phase 2 clinical trial of Brilacidin-OM for oral mucositis, is expected to begin in the second week of the month. Also, this month CTIX<\/a> <\/strong>has a meeting with the FDA to discuss the advancement of the clinical development of two of its major drugs. The company will also be attending a conference from Dec 4 to Dec 6, taking place in Florida. With so much announcements, it’s no wonder the PR brought positive attention to the stock.<\/p>\n

On Oct 30 the company filed a Form S-3, which would allow it to raise up to $75 million in equity and\/or debt financing. Then on Nov 10, the company turned in a Form S-3 Amendmend, as a pre-effective Amendment No.1 to the form. On Nov 19 the SEC gave the registration statement a green light, as there is now an Effect found on the company’s OTC profile.<\/p>\n

On Nov 10, the company also filed its latest quarterly report, which covered the period ended Sept 30. For these three months, CTIX<\/a> <\/strong>reported:<\/p>\n